Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study

Abstract Introduction Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab‐treated multiple sclerosis (MS) patients. Six‐monthly testing has been suggested for anti‐JCV antibody negative patients and patients with low antibod...

Full description

Bibliographic Details
Main Authors: Michael Auer, Harald Hegen, Johann Sellner, Katrin Oppermann, Gabriel Bsteh, Franziska Di Pauli, Thomas Berger, Florian Deisenhammer
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Brain and Behavior
Subjects:
antibodies
JCV
multiple sclerosis
natalizumab
progressive multifocal leukoencephalopathy
risk
Online Access:https://doi.org/10.1002/brb3.1332

Internet

https://doi.org/10.1002/brb3.1332

Similar Items